Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: methotrexate

Opioid Investigated to Treat Acute & Chronic OA Pain; Plus New RA Treatment & More

Michele B. Kaufman, PharmD, BCGP  |  January 20, 2016

In Phase 2 trials, the oral opioid, CR845, has proved promising in treating pain in patients with hip and knee osteoarthritis. Olokizumab is being investigated to treat RA, and in Canada, adalimumab has been approved to treat polyarticular JIA in 2–4 year-olds…

Filed under:AnalgesicsConditionsDrug UpdatesPain Syndromes Tagged with:adalimumabCanadaChronic painchronic pruritushiphip painInternationalKnee Osteoarthritis (OA)olokizumabOsteoarthritisPainRheumatoid Arthritis (RA)

FDA Approves New Drugs for Pain

Michele B. Kaufman, PharmD, BCGP  |  January 19, 2016

FDA Updates Belbuca, buccal-administered buprenorphine, has received U.S. Food and Drug Administration (FDA) approval for treating severe chronic pain.1 The dosage form is a dissolving film that is absorbed through the inner lining of the cheek for chronic pain management. It’s expected to be commercially available in the first quarter of 2016. Seven dosage strengths…

Filed under:AnalgesicsDrug Updates Tagged with:DrugsFDAOsteoarthritisPainrheumatologySafety

The ACR/ARHP Award Winners Discuss Their Contributions to Rheumatology

Richard Quinn  |  January 19, 2016

At the 2015 ACR/ARHP Annual Meeting in San Francisco in November, the ACR and the ARHP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. In the December 2015 issue, The Rheumatologist reported on the ACR’s awards. This month, we speak with the ARHP winners about…

Filed under:AwardsCareer DevelopmentProfessional Topics Tagged with:ACR/ARHPAmerican College of Rheumatology (ACR)Association of Rheumatology Professionals (ARP)Awardswinner

Pharmaceutical Care Models, Tools for Treating Patients with Rheumatoid Arthritis

Louise Grech, BPharm (Hons), MPhil, MRPharmS, Victor Ferrito, BSc, MSc, PhD, CSci, Liberato Camilleri, BEd, MSc, PhD, Anthony Serracino Inglott, BPharm, PharmD, MRPharmS, & Lilian M. Azzopardi, BPharm (Hons), MPhil, PhD, MRPharmS  |  January 19, 2016

Rheumatoid arthritis (RA) can be defined as a chronic autoimmune systemic inflammatory condition characterized by symmetrical polyarthritis. Typically, patients present with pain, stiffness and warmth of the affected joints. The condition can result in extra-articular features, adding to disability, and may eventually lead to premature death, especially if not treated early and appropriately.1,2 Over the…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Drugspatient carepharmaceuticalRheumatoid arthritistherapyTreatment

How to Choose the xBest Course of Treatment to Manage Rheumatoid Arthritis

How to Choose the Best Course of Treatment to Manage Rheumatoid Arthritis

Karen Appold  |  January 19, 2016

Diagnosing rheumatoid arthritis (RA) early in the disease process is ideal, because treatments are more likely to be effective and less damage will occur. Guidelines from the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) state that using newer biologic medications, in addition to more aggressive dosing of traditional medications, is…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Managementpatient careRheumatoid arthritistherapyTreatment

Diagnostic Imaging in Lupus Patient with Foot Pain: Findings

Cianna Leatherwood, MD, & Derrick J. Todd, MD, PhD  |  January 19, 2016

View the question. Findings/Diagnosis An anteroposterior (AP) radiograph of the right foot shows hallux valgus of the first metatarsal phalangeal (MTP) joint, erosive changes at the first and fifth metatarsal bones and degenerative changes at the fourth and fifth metatarsal-cuboid joints. An AP radiograph of the left foot shows extensive erosive and degenerative changes at…

Filed under:ConditionsSoft Tissue PainSystemic Lupus Erythematosus Tagged with:deformitydiagnosticfootimagingLupusPainSLESystemic lupus erythematosusUltrasound

Medicare Drug Coverage Plans for Rheumatologic Medications

From the College  |  January 19, 2016

Different parts of Medicare cover different services. For outpatient prescription drugs, Medicare has two distinct programs with a maze of complex policies. Most physicians along with Medicare patients, retail pharmacies, Medicare drug plans as well as Medicare Advantage health plans continuously struggle with navigating Medicare drug coverage under Part B and Part D. There are…

Filed under:From the College Tagged with:Centers for Medicare & Medicaid Services (CMS)costscoverageDrugsMedicarerheumatology

Biosimilars Seek Regulatory Approval in the U.S. & Europe; Plus MTX Underused in the U.S.

Michele B. Kaufman, PharmD, BCGP  |  January 6, 2016

In Europe, an etanercept biosimilar is getting closer to being approved to treat RA and more, and in the U.S., an application for an adalimumab biosimilar has been submitted for FDA approval. Also, an analysis of methotrexate use in the U.S. shows that therapy may actually be underused for RA…

Filed under:Biologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:axial spondyloarthritis (SpA)BiosimilarsEuropean Medicines AgencyMethotrexateplaque psoriasisPsoriatic ArthritisRheumatoid Arthritis (RA)

The Microbiome’s Role in Inflammatory Arthritis

Arthritis & Rheumatology  |  January 1, 2016

Despite the relative novelty of the human microbiome as an area of study, a substantial body of evidence has accumulated addressing its potential involvement in the pathogenesis of rheumatic disease. This review article explores the available data in animal and human studies, focusing on the role of the intestinal microbiome in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and the spondyloarthritidies (SpA)…

Filed under:Axial SpondyloarthritisConditionsPsoriatic ArthritisRheumatoid Arthritis Tagged with:gut microbeMicrobiomePsoriatic Arthritis

Biologic DMARDs Prove Effective for Psoriatic Arthritis & Combination DMARDs Show Promise for RA

Michele B. Kaufman, PharmD, BCGP  |  December 25, 2015

In clinical trials, ixekizumab and adalimumab proved safe and effective in treating adults with active psoriatic arthritis. Also, the combination therapy of certolizumab pegol plus methotrexate was more effective than placebo for treating severe RA…

Filed under:Biologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:adalimumabBiologicsCertolizumab Pegolcombination therapyixekizumabMethotrexatePsoriatic ArthritisRheumatoid Arthritis (RA)

  • « Previous Page
  • 1
  • …
  • 70
  • 71
  • 72
  • 73
  • 74
  • …
  • 106
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences